Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

November 12, 2024 | Last Trade: US$5.06 0.05 1.00

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7^th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Jefferies London Healthcare Conference

Fireside Chat: Tuesday, November 19, 2024, at 11:30 a.m. GMT in London, UK
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Tuesday, November 19

7^th Annual Evercore HealthCONx Conference

Fireside Chat: Tuesday, December 3, 2024, at 1:20 p.m. EST in Coral Gables, Florida
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Tuesday, December 3

Citi Global Healthcare Conference

Management will participate in one-on-one meetings on Wednesday, December 4 in Miami, Florida

A webcast of both fireside chats can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.

About Foghorn Therapeutics

Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$5.06
Daily Change:	0.05 1.00
Daily Volume:	74,799
Market Cap:	US$286.040M

August 05, 2025 Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update May 14, 2025 Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update May 01, 2025 Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors April 28, 2025 Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update April 15, 2025 Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting LOAD MORE NEWS

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE